| 免疫检查点抑制剂疗效相关生物标志物的研究进展 |
| |
| 引用本文： | 杨雯雯,田宏伟,雷彩宁,黄显斌,景武堂,靳川伟,宋绍明,龚世怡,郭天康. 免疫检查点抑制剂疗效相关生物标志物的研究进展[J]. 肿瘤防治研究, 2022, 49(5): 484-489. DOI: 10.3971/j.issn.1000-8578.2022.21.1175 |
| |
| 作者姓名： | 杨雯雯 田宏伟 雷彩宁 黄显斌 景武堂 靳川伟 宋绍明 龚世怡 郭天康 |
| |
| 作者单位： | 1. 730000 兰州，兰州大学第一临床医学院；2. 730000 兰州，甘肃省人民医院普外科；3. 730000 兰州，甘肃中医药大学第一临床医学院 |
| |
| 基金项目： | 甘肃省自然科学基金(20JR10RA403)；;甘肃省青年科技基金(21JR7RA641)~~； |
| |
| 摘 要： | 近年来，以免疫检查点为靶点的免疫疗法在多种晚期实体肿瘤中取得了革命性的突破，尽管长期疗效非常显著，但仅限于一小部分肿瘤患者。有些患者会产生耐药及免疫相关不良事件（irAEs）。免疫检查点抑制剂（ICIs）主要包括靶向细胞毒性T淋巴细胞抗原-4的抗体以及靶向程序性细胞死亡受体-1及其配体的抗体。因此，筛选可能受益于免疫疗法人群的潜在生物标志物，以最大程度提高治疗效益是重中之重。本文就ICIs作用机制及其相关疗效生物标志物方面进行综述，以更好地指导免疫治疗在临床中的应用。
|
| 关 键 词： | 免疫治疗 免疫检查点抑制剂 生物标志物 |
| 收稿时间： | 2021-10-18 |
Research Progress of Efficacy Biomarkers Related to Immune Checkpoint Inhibitors |
| |
| YANG Wenwen,TIAN Hongwei,LEI Caining,HUANG Xianbin,JING Wutang,JIN Chuanwei,SONG Shaoming,GONG Shiyi,GUO Tiankang. Research Progress of Efficacy Biomarkers Related to Immune Checkpoint Inhibitors[J]. Cancer Research on Prevention and Treatment, 2022, 49(5): 484-489. DOI: 10.3971/j.issn.1000-8578.2022.21.1175 |
| |
| Authors: | YANG Wenwen TIAN Hongwei LEI Caining HUANG Xianbin JING Wutang JIN Chuanwei SONG Shaoming GONG Shiyi GUO Tiankang |
| |
| Affiliation: | 1. The First School of Clinical Medicine, Lanzhou University, Lanzhou 730000, China; 2. Department of General Surgery, Gansu Provincial People’s Hospital, Lanzhou 730000, China; 3. The First Clinical Medical College of Gansu University of Chinese Medicine, Lanzhou 730000, China |
| |
| Abstract: | In recent years, immunotherapy with immune checkpoint as the target has made revolutionary breakthroughs in the treatment of a variety of advanced solid tumors. Notwithstanding the impressive long-term therapeutic benefits, their efficacy is limited to a small subset of cancer patients. Some patients experienced drug resistance and immune-related adverse events (irAEs). Immune checkpoint inhibitors (ICIs) primarily include antibodies targeting CTLA-4 and antibodies targeting PD-1 and its ligands. Thus, it is of utmost importance to screen potential biomarkers in populations that may benefit from immunotherapy, to maximize therapeutic benefits. This review summarizes the mechanism of ICIs and its related efficacy biomarker, to better guide the application of immunotherapy in clinical practice. |
| |
| Keywords: | Immunotherapy Immune checkpoint inhibitors Biomarkers |
|
| 点击此处可从《肿瘤防治研究》浏览原始摘要信息 |
|
点击此处可从《肿瘤防治研究》下载全文 |
|
